Cidara Therapeutics, Inc. CDTX
221.38 USD 0.00 (+0.00%)
Jan 8, 2026, 9:30 AM EST
221.38 Day range 221.38
52-week range unavailable
- YTD
- +0.22%
- 1 year
- +725.74%
News
defenseworld.net Cidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Above Fifty Day Moving Average – Should You Sell? Cidara Therapeutics, Inc. (NASDAQ: CDTX - Get Free Report) shares crossed above its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $220.52 and traded as high…
feeds.benzinga.com Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight Pharmaceuticals giant, Merck and Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32…
benzinga.com Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight Pharmaceuticals giant, Merck & Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32…
defenseworld.net 3,187 Shares in Cidara Therapeutics, Inc. $CDTX Bought by ANB Bank ANB Bank bought a new position in shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX) during the undefined quarter, according to its most recent disclosure with the SEC. The fund bought 3,187 shares…
defenseworld.net Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Recommendation of “Hold” from Analysts Cidara Therapeutics, Inc. (NASDAQ: CDTX - Get Free Report) has been assigned a consensus recommendation of "Hold" from the twelve brokerages that are presently covering the company, MarketBeat.com…
fool.com Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? HighVista Strategies initiated a position in Cidara Therapeutics, buying 70,904 shares valued at $6.79 million. The position represents 1.66% of 13F reportable assets under management (AUM).
defenseworld.net Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of “Hold” from Brokerages Shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX - Get Free Report) have received a consensus recommendation of "Hold" from the twelve research firms that are covering the stock, Marketbeat.com…
seekingalpha.com 3 Potential Mid-Cap Biotech Buyout Targets In 2026 The biotech sector began December with notable weakness, as both IBB and XBI ETFs declined over two percent during trading on Monday. The sector has bounced back since. However, small biotech stocks…
defenseworld.net Geode Capital Management LLC Grows Stock Position in Cidara Therapeutics, Inc. $CDTX Geode Capital Management LLC grew its position in shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX) by 576.6% during the second quarter, according to its most recent filing with the Securities and…
prnewswire.com Halper Sadeh LLC Encourages GIFI, MOVE, RMBI, CDTX Shareholders to Contact the Firm to Discuss Their Rights Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Nov. 28, 2025 Halper Sadeh LLC, an investor
globenewswire.com HAPPY THANKSGIVING AND ALERT: The M&A Class Action Firm Continues to Investigate the Merger – EXAS, SEE, CDTX, and MRSN NEW YORK, Nov. 27, 2025 (GLOBE NEWSWIRE) -- We wish you a Happy Thanksgiving and Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), who has…
proactiveinvestors.co.uk hVIVO gains validation from Cidara's takeover; broker calls it a "glowing endorsement" Merck's agreement to acquire Cidara Therapeutics for about $9.2 billion gives hVIVO PLC (AIM:HVO) a moment of reflected glory. Peel Hunt's analysts highlight that Cidara's lead antiviral, CD388,…
proactiveinvestors.co.uk hVIVO hails $9.2 billion Cidara takeover after key trial wins hVIVO PLC (AIM:HVO) has praised its long-running partner Cidara Therapeutics after the American biotech agreed to be bought by MSD in a deal worth about $9.2 billion, saying the takeover highlights…
globenewswire.com Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations Target enrollment of 6,000 participants completed in the Northern Hemisphere Planned interim analysis in Q1 2026 will determine potential need for additional enrollment during Southern Hemisphere flu…
prnewswire.com SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-NUVSF, NDTAF, THS, and CDTX NEW YORK , Nov. 21, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is…
fool.com Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way
fool.com Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs? The pharmaceutical giant's post-Keytruda plans continue to take shape.
fool.com Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. Merck has announced plans to acquire Cidara Therapeutics for $9.2 billion, or $221.50 per share. Representing a heavy premium to the biotech's prior trading price, the bid caused its shares to surge.
forbes.com Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025 In this week's edition of InnovationRx, we look at the biotech deal frenzy, Recursion's incoming CEO, the infant formula botulism outbreak, and more. To get it in your inbox, subscribe here.
marketbeat.com Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything In one of the most decisive strategic moves in the biotech sector this year, pharmaceutical titan Merck & Co. NYSE: MRK has committed a formidable $9.2 billion in cash to acquire Cidara Therapeutics…
fool.com This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared-but seemingly missed out on a massive premium by mere weeks.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com Gold Tumbles Over 2%; Cidara Therapeutics Shares Spike Higher 
benzinga.com Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday 
benzinga.com Nasdaq Dips Over 300 Points; Applied Materials Posts Upbeat Q4 Earnings 
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Why RLX Technology Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket 
benzinga.com Earnings Scheduled For November 6, 2025 
benzinga.com Janus Henderson, Avidity Biosciences, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday 
benzinga.com Earnings Scheduled For August 7, 2025 
benzinga.com Why BlackBerry Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com Earnings Scheduled For May 8, 2025 
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - benzinga.com Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- benzinga.com Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- benzinga.com Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
- benzinga.com Why Core & Main Are Trading Lower By 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers Palisade Bio, Inc. (NASDAQ: PALI) shares jumped 114% to $1.47. Palisade Bio transformed GI-focused pipeline through exclusive worldwide licensing agreement with Giiant Pharma, Inc. for…
- benzinga.com Cidara Therapeutics And 3 Other Stocks Under $3 Insiders Are Buying The Dow Jones closed lower by over 150 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders…
- benzinga.com Why Alibaba Shares Are Trading Higher By Over 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers
benzinga.com Why FreightCar America Shares Are Trading Lower By 8%; Here Are 20 Stocks Moving Premarket Gainers Biodexa Pharmaceuticals (NASDAQ: BDRX) shares rose 76% to $0.8276 in pre-market trading after gaining 65% on Monday.
benzinga.com Why Scholastic Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers Near Intelligence Inc. (NASDAQ: NIR) shares climbed 53.1% to $16.50.- benzinga.com Why Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers DiamondHead Holdings Corp. (NASDAQ: DHHC) shares jumped 104.2% to $21.15. DiamondHead entered into convertible note purchase agreement dated March 21, 2023.
- benzinga.com Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland.
- benzinga.com Why FARO Technologies Shares Are Trading Lower By 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 133.1% to $0.2870. Helbiz recently announced discontinuation of operations in non-profitable markets.
- benzinga.com Stocks That Hit 52-Week Lows On Monday Monday's session saw 84 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's trading, 505 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's session, 445 companies made new 52-week lows.